We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genzyme Pays $32.5M, Signs Deferred Prosecution Pact For Seprafilm Misbranding

(September 15, 2015, 7:42 AM EDT) -- TAMPA, Fla. — U.S. Judge Elizabeth A. Jenkins of the Middle District of Florida on Sept. 4 approved a two-year deferred prosecution agreement under which Genzyme Corp. will pay $32,587,439 for promoting off-label uses of its Seprafilm medical device (United States of America v. Genzyme Corporation, No. 15-cr-352, M.D. Fla., Tampa Div.).

(Deferred prosecution agreement in Section A. Document #28-150917-003X.)

A criminal information and the deferred prosecution agreement were filed against Genzyme on Sept. 3 in the U.S. District Court for the Middle District of Florida....
To view the full article, register now.